Arvinas Inc (ARVN)

Feb 12, 2025, 12:04 PM EST - 10 days ago

These Analysts Revise Their Forecasts On Arvinas After Q4 Results

Feb 11, 2025, 3:22 PM EST - 11 days ago

Arvinas, Inc. (ARVN) Q4 2024 Earnings Call Transcript

Feb 11, 2025, 7:00 AM EST - 11 days ago

Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Feb 3, 2025, 7:00 AM EST - 19 days ago

Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

Jan 10, 2025, 7:00 AM EST - 6 weeks ago

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

Dec 10, 2024, 9:05 AM EST - 2 months ago

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

Dec 4, 2024, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Shareholders to Learn More About the Investigation

Dec 3, 2024, 10:00 AM EST - 2 months ago

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Dec 2, 2024, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation

Dec 1, 2024, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect

Nov 29, 2024, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Investors to Connect

Nov 28, 2024, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Stockholders to Inquire about Securities Investigation

Nov 27, 2024, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Investors to Learn More About the Investigation

Nov 27, 2024, 7:00 AM EST - 3 months ago

Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 10:00 AM EST - 3 months ago

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Nov 25, 2024, 5:35 PM EST - 3 months ago

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium

Nov 25, 2024, 10:00 AM EST - 3 months ago

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Nov 24, 2024, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Stockholders to Learn More About the Investigation

Nov 22, 2024, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Investors to Inquire about Securities Investigation

Nov 21, 2024, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Investors to Reach Out

Nov 20, 2024, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Stockholders to Reach Out

Nov 4, 2024, 7:00 AM EST - 3 months ago

Arvinas to Participate in Upcoming Investor Conferences

Oct 30, 2024, 3:43 PM EDT - 4 months ago

Arvinas, Inc. (ARVN) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 7:00 AM EDT - 4 months ago

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 22, 2024, 4:05 PM EDT - 4 months ago

Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day

Oct 21, 2024, 7:00 AM EDT - 4 months ago

Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024

Jul 19, 2024, 2:15 PM EDT - 7 months ago

Undercovered Dozen: Spirit Airlines, HubSpot, Cigna, First Quantum Minerals +

CI HUBS FLNG GRFS IGR INTR KREF

Jun 24, 2024, 4:37 PM EDT - 8 months ago

Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

Jun 21, 2024, 7:00 AM EDT - 8 months ago

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2

Jun 17, 2024, 7:00 AM EDT - 8 months ago

Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D.

May 29, 2024, 2:45 PM EDT - 9 months ago

3 Of My Favorite Names On Wells Fargo's Biotech Buyout List

AXSM CYTK NTLA NVS PFE REGN VKTX

May 23, 2024, 5:00 PM EDT - 9 months ago

Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

May 16, 2024, 6:00 AM EDT - 10 months ago

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)

May 9, 2024, 4:42 PM EDT - 10 months ago

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

May 7, 2024, 7:00 AM EDT - 10 months ago

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 24, 2024, 4:30 PM EDT - 10 months ago

Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer

Apr 11, 2024, 3:50 PM EDT - 11 months ago

Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation

NVS

Apr 11, 2024, 11:31 AM EDT - 11 months ago

Arvinas inks over $1.0 billion deal with Novartis

NVS

Apr 11, 2024, 7:00 AM EDT - 11 months ago

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer